We are live on ! Find out more
BLPH

Bellerophon Therapeutics

Delisted

BLPH was delisted on the 13th of October, 2023.

15 hedge funds and large institutions have $8.35M invested in Bellerophon Therapeutics in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

25,822% more capital inflows, than outflows

Capital inflows: $8.89M | Capital outflows: $34.3K

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

5.31% more ownership

Funds ownership: 44.77% → 50.07% (+5.3%)

0% more funds holding

Funds holding: 15 → 15 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

BLPH Hedge Fund Activity: Q4 2016 in Review

15 of the 4,007 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics (BLPH) for Q4 2016, worth a combined $8.35M — down 8.1% from $9.09M a quarter earlier.

Fund positioning in BLPH was balanced in Q4 2016: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 1 trimmed.

The largest buyer was New Mountain Capital, adding an estimated $5.3M. The largest seller was Virtu KCG Holdings, cutting an estimated $19.3K.

  • 15 institutional investors held Bellerophon Therapeutics (BLPH) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $8.35M of Bellerophon Therapeutics stock for Q4 2016, down 8.1% quarter-over-quarter.
  • 3 funds opened new Bellerophon Therapeutics positions in Q4 2016 and 3 closed out, a net change of 0 holders.
  • The largest Bellerophon Therapeutics buyer in Q4 2016 was New Mountain Capital, an estimated $5.3M added.
  • The largest Bellerophon Therapeutics seller in Q4 2016 was Virtu KCG Holdings, an estimated $19.3K sold.

Based on aggregated 13F filings for Q4 2016.